Status:

ACTIVE_NOT_RECRUITING

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Lead Sponsor:

Immunovant Sciences GmbH

Conditions:

Generalized Myasthenia Gravis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams...

Eligibility Criteria

Inclusion

  • Are ≥ 18 years of age at the Screening Visit.
  • Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification Class II, III, or IVa at the Screening Visit.
  • Have a QMG score ≥ 11 at the Screening and Baseline Visits.
  • Have a MG-ADL score of ≥ 5 at the Screening and Baseline Visits.
  • Additional inclusion criteria are defined in the protocol.

Exclusion

  • Have experienced myasthenic crisis within 3 months of the Screening Visit.
  • Have had a thymectomy performed \< 6 months prior to the Screening Visit or have a planned thymectomy during the study period.
  • Have any active or untreated malignant thymoma.
  • Have received any agent or therapy (exclusive of those identified within inclusion criteria) with immunosuppressive properties (e.g., stem cell therapy, chemotherapies) within the past year.
  • Have used anti-FcRn treatment within 3 months prior to the Screening Visit or have a documented history of non-response to prior anti-FcRn treatment.
  • Additional exclusion criteria are defined in the protocol.

Key Trial Info

Start Date :

June 27 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2025

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT05403541

Start Date

June 27 2022

End Date

April 1 2025

Last Update

August 7 2024

Active Locations (105)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 27 (105 locations)

1

Site Number -1022

Phoenix, Arizona, United States, 85028

2

Site Number -1029

Scottsdale, Arizona, United States, 85251

3

Site Number -1002

Carlsbad, California, United States, 92011

4

Site Number -1009

Irvine, California, United States, 92697